Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Belon reported for 6 months of 2023 by IFRS

8/30/23 BLNG

Red October reported for 6 months of 2023 by IFRS

8/30/23 KROT

Slavneft-Megionneftegaz reported for 6 months of 2023 by IFRS

8/30/23 MFGS

Rosinter Restaurants Holding reported for 6 months of 2023 by IFRS

8/30/23 ROST

European Electrotechnics reported for 6 months of 2023 by IFRS

8/30/23 EELT

Etalon reported for 6 months of 2023

8/30/23 ETLN

Rosneft's gas production increased by 31.8% in the first half of the year

8/30/23 ROSN

PhosAgro reduced fertilizer sales by 4.3% in the first half of the year

8/30/23 PHOR

Inter RAO started construction of the Novolenskaya TPP in Yakutia

8/30/23 IRAO

PIK reported for 6 months of 2023 by IFRS

8/30/23 PIKK